ZFN

Global Rat Model Market to Reach $2.41 Billion by 2030 with a CAGR of 7.06%: Key Insights and Growth Factors Unveiled

Retrieved on: 
Tuesday, October 31, 2023
Rat, Gene editing, Human, Incidence, Molecular biology, Therapy, Vaccine, Dihydrolipoyllysine-residue (2-methylpropanoyl)transferase, Toxicology, CRISPR, Prevalence, Embryonic stem cell, Human Genome Project, Phenotype, Research, Application, Microinjection, Growth, Disease, COVID-19, Breeding, Outcrossing, Envigo, USD, ZFN, GEM, Agriculture, Medical device

The global rat model market size is expected to reach USD 2.41 billion by 2030., expanding at a CAGR of 7.06% from 2023 to 2030.

Key Points: 
  • The global rat model market size is expected to reach USD 2.41 billion by 2030., expanding at a CAGR of 7.06% from 2023 to 2030.
  • Genetically modified organisms are extensively used in research for identifying potential therapeutic targets and further validation of the same.
  • The extensive healthcare-based research has driven the market for understanding diseases and genetic illnesses of humans.
  • Increased spending on research and growing number of clinical trials are the key factors contributing to the market growth.

Allogeneic CAR Cell Therapy Market Surges in Response to Advancements in Gene Editing and IP Trends - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Health, Genetics, Other Science, Research, Science, Biotechnology, Patent, IP, IPSC, Abstract, Microsoft Excel, Traction, Graft-versus-host disease, Intellectual property, TALEN, Safety, Cancer, FDA, Allotransplantation, CRISPR, Growth, Database, European Patent Convention, CAR, Bone marrow, Gene editing, ZFN, NK, Attention, Vaccine, Pharmaceutical industry

The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.

Key Points: 
  • The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.
  • IP Trends Fuel Growth: The analysis of patent publications reveals that interest in allogeneic CAR therapies began in the late 2000s.
  • Advantages of Allogeneic CAR: Allogeneic CAR therapies offer several advantages over autologous CAR therapies, including faster production (10-11 days vs. over three weeks), scalability, standardization, and reduced manufacturing costs.
  • The report profiles key players in the allogeneic CAR cell therapy market, offering insights into their patent portfolios, geographical coverage, IP trends, and clinical trials.

Global Genome Editing Market Report 2023: Players Include Sangamo Therapeutics, Precision Biosciences, Cellectis, Merck and Lonza - ResearchAndMarkets.com

Retrieved on: 
Friday, June 16, 2023
Health, Genetics, Genome Canada, Vaccine, CRISPR, DNA, ZFN, Biotechnology, Prevalence, Agriculture, COVID-19, MEA, Research, Medicine, Genomics, Genome, USD, Cas9, Forecasting, Government, Ministry, Incidence, Investment, Engineering, Plant growth analysis, Delivery, Mode, Growth, TALEN, Environment, Gene, Disease, Antibiotics, Fine chemical, Science, Application

As a result, the Genome Editing Market will increase favourably during the period of forecasting.

Key Points: 
  • As a result, the Genome Editing Market will increase favourably during the period of forecasting.
  • Recently, the market has grown primarily due to the expanding usage of CRISPR genome editing technology and increased demand for synthetic genes in various biotechnology fields.
  • The Global Genome Editing Market is segmented based on Technology, Delivery Method, Mode, End-use, Application, and Region.
  • Genome editing and engineering technologies have gained prominence because to the rising demand for vaccines and antiviral candidates; these reasons are anticipated to propel the genome editing market in the years to come.

Genome Engineering Global Market Report 2022: Increasing Development of Novel Technologies Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Health, Genetics, MHRA, Biotechnology, Genome, NIH, Metabolic gene cluster, Pioneer program, Next Generation, Haemophilia, Drug discovery, DNA, Cancer, TALEN, Medicines and Healthcare products Regulatory Agency, Agriculture, Research, Precision medicine, Integration, CTA, Investment, Genetic engineering, Integrated DNA Technologies, Genomics, Growth, Medication, Application, ZFN, Sense (molecular biology), Antibiotics, Pharmaceutical industry, CRISPR

The global genome engineering market is anticipated to witness an impressive growth during the forecast period.

Key Points: 
  • The global genome engineering market is anticipated to witness an impressive growth during the forecast period.
  • The increasing funding and investments in the study and development of new genetic engineering technologies is expected to create lucrative opportunities for the growth of genome engineering market in the coming years.
  • This in turn will create lucrative opportunities for the growth of global genomic engineering market over the next few years.
  • In this report, Global Genome Engineering market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Insights on the CRISPR Global Market to 2028 - Rising Age-related Disorders are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022
Health, Genetics, Research, ZFN, Genetic engineering, Technology, Fatality, TALEN, Growth, Drug discovery, Gene editing, Prevalence, Government, Marketing, Agriculture, CRISPR

Patent infringement and ethical issues associated with the misuse of CRISPR gene editing tools are estimated to hamper the growth of the market.

Key Points: 
  • Patent infringement and ethical issues associated with the misuse of CRISPR gene editing tools are estimated to hamper the growth of the market.
  • The global CRISPR market is segmented based on the application and end-user.
  • Analysis of regional regulations and other government policies impacting the global CRISPR market.
  • Insights about market determinants that are stimulating the global CRISPR market.

Genome Editing Market Size to Grow USD 6739.8 Million by 2028 at a CAGR of 9.3% | Valuates Reports

Retrieved on: 
Monday, September 5, 2022
Genome, COVID-19, Technology, Synthetic biology, Cancer, Research, TALEN, Agriculture, Disease, Gene editing, Engineering, Immortalised cell line, Vaccine, US FDA, Death, USD, Incidence, Government, GM, Hepatitis, Forest Law Enforcement and Governance Program, Infection, TB, Investment, HIV, MD, CRISPR, Prevalence, CAGR, A-DNA, Modified starch, B cell, GAPP, ZFN, Genomics, Growth, Malaria, CDC, Industry, Lists of diseases, HIV/AIDS, Patient

The global Genome Editing market size is projected to reach USD 6739.8 Million by 2028, from USD 3513 Million in 2021, at a CAGR of 9.3% during 2022-2028.

Key Points: 
  • The global Genome Editing market size is projected to reach USD 6739.8 Million by 2028, from USD 3513 Million in 2021, at a CAGR of 9.3% during 2022-2028.
  • The increase in demand for synthetic biology in both developed and developing nations is what is fueling the expansion of the gene editing market.
  • The expansion of the genome editing market is anticipated to be fueled by an increase in the number of cancer patients.
  • The opportunity for the gene editing market segment will expand with the rising demand for CRISPR/Cas9 for genome analysis to find genetic abnormalities and its therapeutic discovery.

Genome Editing Market Size to Grow USD 6739.8 Million by 2028 at a CAGR of 9.3% | Valuates Reports

Retrieved on: 
Monday, September 5, 2022
Genome, COVID-19, Technology, Synthetic biology, Cancer, Research, TALEN, Agriculture, Disease, Gene editing, Engineering, Immortalised cell line, Vaccine, US FDA, Death, USD, Incidence, Government, GM, Hepatitis, Forest Law Enforcement and Governance Program, Infection, TB, Investment, HIV, MD, CRISPR, Prevalence, CAGR, A-DNA, Modified starch, B cell, GAPP, ZFN, Genomics, Growth, Malaria, CDC, Industry, Lists of diseases, HIV/AIDS, Patient

The global Genome Editing market size is projected to reach USD 6739.8 Million by 2028, from USD 3513 Million in 2021, at a CAGR of 9.3% during 2022-2028.

Key Points: 
  • The global Genome Editing market size is projected to reach USD 6739.8 Million by 2028, from USD 3513 Million in 2021, at a CAGR of 9.3% during 2022-2028.
  • The increase in demand for synthetic biology in both developed and developing nations is what is fueling the expansion of the gene editing market.
  • The expansion of the genome editing market is anticipated to be fueled by an increase in the number of cancer patients.
  • The opportunity for the gene editing market segment will expand with the rising demand for CRISPR/Cas9 for genome analysis to find genetic abnormalities and its therapeutic discovery.

Global Genome Engineering Market to Surpass US$ 15,195.74 Million by 2030 - Coherent Market Insights

Retrieved on: 
Friday, July 15, 2022
Research, Thermo Fisher Scientific, RNA, Mindful Scientific Inc., Cancer, Streptomyces, ALS, Genome, CRISPR, Gene editing, CAGR, DSB, Technology, National academy, DNA, Genome instability, Pfizer, National Center for Biotechnology Information, National, US, Sangamo Therapeutics, Intellia Therapeutics, Merck Group, Gilead Sciences, PNAS, Growth, Analysis, ZFN, Amyotrophic lateral sclerosis, Pharmaceutical industry, Antibiotics

SEATTLE, July 15, 2022 /PRNewswire/ --According to Coherent Market Insights, the global genome engineering market is estimated to be valued at US$ 5,205.60 million in 2022 and is expected to exhibit a CAGR of 14.3% during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, July 15, 2022 /PRNewswire/ --According to Coherent Market Insights, the global genome engineering market is estimated to be valued at US$ 5,205.60 million in 2022 and is expected to exhibit a CAGR of 14.3% during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Genome Engineering Market:
    Strategic collaboration of key players in market for genome engineering technologies is also expected to positively affect market growth.
  • Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth over the forecast period.
  • Global genome engineering market is expected to exhibit a CAGR of 14.3% during the forecast period due to increasing research and development genome engineering technology.

Global Genome Engineering Market to Surpass US$ 15,195.74 Million by 2030 - Coherent Market Insights

Retrieved on: 
Friday, July 15, 2022
Research, Thermo Fisher Scientific, RNA, Mindful Scientific Inc., Cancer, Streptomyces, ALS, Genome, CRISPR, Gene editing, CAGR, DSB, Technology, National academy, DNA, Genome instability, Pfizer, National Center for Biotechnology Information, National, US, Sangamo Therapeutics, Intellia Therapeutics, Merck Group, Gilead Sciences, PNAS, Growth, Analysis, ZFN, Amyotrophic lateral sclerosis, Pharmaceutical industry, Antibiotics

SEATTLE, July 15, 2022 /PRNewswire/ --According to Coherent Market Insights, the global genome engineering market is estimated to be valued at US$ 5,205.60 million in 2022 and is expected to exhibit a CAGR of 14.3% during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, July 15, 2022 /PRNewswire/ --According to Coherent Market Insights, the global genome engineering market is estimated to be valued at US$ 5,205.60 million in 2022 and is expected to exhibit a CAGR of 14.3% during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Genome Engineering Market:
    Strategic collaboration of key players in market for genome engineering technologies is also expected to positively affect market growth.
  • Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth over the forecast period.
  • Global genome engineering market is expected to exhibit a CAGR of 14.3% during the forecast period due to increasing research and development genome engineering technology.

CSE Bulletin: New Listing - GeneTether Therapeutics Inc. (GTTX)

Retrieved on: 
Monday, March 28, 2022
Therapy, Zinc finger nuclease, ZFN, DNA, CRISPR, Disclosure, TALEN, Efficiency, CSE

Toronto, Ontario--(Newsfile Corp. - Le 28 mars/March 2022) - The common shares of GeneTether Therapeutics Inc., have been approved for listing on the CSE.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - Le 28 mars/March 2022) - The common shares of GeneTether Therapeutics Inc., have been approved for listing on the CSE.
  • GeneTether Therapeutics is an innovative genetic medicines company focused on creating best-in-class gene editing therapies based on our proprietary GeneTether platform.
  • Les actions ordinaires de GeneTether Therapeutics Inc., ont t approuves pour tre inscrites au CSE.
  • GeneTether Therapeutics est une socit de mdicaments gntiques innovante qui se concentre sur la cration des meilleures thrapies d'dition de gnes bases sur notre plateforme exclusive GeneTether.